A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT03215030. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Part 2: To assess clinical activity of one or more dosing schedules of modakafusp alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with one or more selected dose of modakafusp alfa in selected group of participants. Part 3: To find the optimal dose with the more favorable risk-benefit profile of modakafusp alfa. Participants will receive modakafusp alfa at one of two doses which will be given through a vein.
Study identification
- NCT ID
- NCT03215030
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 272 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 4, 2017 (Actual)
- Primary completion
- Jul 1, 2024 (Actual)
- Completion
- Nov 7, 2024 (Actual)
- Last update posted
- Jan 29, 2026
2017 – 2024
United States locations
- U.S. sites
- 27
- U.S. states
- 19
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Los Angeles Cancer Network - Glendale Adventist Medical Center | Glendale | California | 91204 | — |
| University of California Irvine | Orange | California | 92868 | — |
| Office of James R. Berenson MD | West Hollywood | California | 90069 | — |
| Smilow Cancer Hospital at Yale New Haven | New Haven | Connecticut | 06520 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern Medicine - Northwestern Medical Group | Chicago | Illinois | 60611 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Investigative Clinical Research of Indiana, LLC | Noblesville | Indiana | 46062 | — |
| June E. Nylen Cancer Center | Sioux City | Iowa | 51101 | — |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Univeristy of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| USOR - Comprehensive Cancer Centers of Nevada - Central Valley | Las Vegas | Nevada | 89119 | — |
| John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| University of Rochester | Rochester | New York | 14627 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Levine Cancer Center | Charlotte | North Carolina | 28402 | — |
| Levine Cancer Institute - Concord | Concord | North Carolina | 28205 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718-2566 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Baptist Cancer Center - Memphis - Walnut Grove | Memphis | Tennessee | 38120 | — |
| Lumi Research | Houston | Texas | 77002 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03215030, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03215030 live on ClinicalTrials.gov.